Minimally Invasive Surgery for Prolactinomas

Prolactinoma is the most common type of hormonally active pituitary adenoma. For the last several decades, the mainstay of treatment for prolactinoma has been medical therapy with dopamine agonists, obtaining adequate tumor control in approximately 90% of cases. However, several situations may require surgical resection: intolerance to the medication due to its side effects, unresponsiveness to the therapy, unwillingness to take the medication, and specific tumor characteristics such as predominantly cystic or hemorrhagic components.

Description

Prolactinoma is the most common type of hormonally active pituitary adenoma. For the last several decades, the mainstay of treatment for prolactinoma has been medical therapy with dopamine agonists, obtaining adequate tumor control in approximately 90% of cases. However, several situations may require surgical resection: intolerance to the medication due to its side effects, unresponsiveness to the therapy, unwillingness to take the medication, and specific tumor characteristics such as predominantly cystic or hemorrhagic components.

In this webinar, I will review our surgical indications and functional outcomes for patients with both microprolactiomas and invasive macroprolactinomas. Our results indicate that minimally invasive endoscopic pituitary surgery, when performed by highly experienced surgeons, achieves endocrinological remission in the majority of cases with low surgical-related complication rates.

 

Leave a comment

You are commenting as guest.